|
|||||
|
|
#1 |
|
|
faulty BRCA2 gene often become resistant to standard drugs. In addition, British scientists now believe they know why. It should be noted that the findings could help doctors spot those patients who stand to benefit most from particular treatments, and also give insights into how medicines lose their effectiveness. As was reported in the journal Nature, researchers at the Institute of Cancer Research in the United Kingdom, noted that healthy BRCA2 is actually a tumor suppressor. Still, it should be noted that a defective form of the gene renders cells incapable of fixing damaged DNA, which in turn encourages malignancy. It is noteworthy of mention that the new research was conducted with both breast and ovarian cancer cells. Further investigation into this report depicts that the research team found that after exposure to standard chemotherapy, some cells mutate back to the normal BRCA2 gene type. They state that this allows the cells to overcome DNA damage but it does not neutralize the tumor. To conclude, Prof. Herbie Newell, executive director of translational research at Cancer Research UK, told the BBC that "The research deepens our understanding of why some breast cancer patients with a faulty BRCA2 gene may stop responding to treatment. This type of research is becoming increasingly important as we seek to tailor cancer therapies to individual patients" Article Posted By Bodyhealthsoul LLC. Stay with us for more information on the Latest Health News, Tips, Healthy Living and Lifestyle choices at http://www.bodyhealthsoul.com |
| Thread Tools | |
| Display Modes | |
|
|